The Duchenne Muscular Dystrophy Market Size (DMD Market) in the 7MM was found to be USD 266.06 Million in 2017, during the study period (2017-2030).
Duchenne Muscular Dystrophy (DMD), approximately affects 1 in 3,500 male births globally. Moreover, Duchenne Muscular Dystrophy prevalence in the 7MM (The US, EU5, and Japan) was found to be approximately 31,386 in 2017 with the diagnosed prevalence of 26,678.
The key players in the Duchenne Muscular Dystrophy Market include like Sarepta Therapeutics, Santhera Pharmaceuticals, Catabasis Pharmaceuticals, Hoffmann-La Roche, FibroGen, Antisense Therapeutics, REVERAGEN BIOPHARMA LIMITED, Italfarmaco, Nobelpharma America, Pfizer, Cumberland Pharma and many others.
For more detailed information visit: https://www.delveinsight.com/blog/duchene-muscular-dystrophy-market/